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Abstract TFE-fusion renal cell carcinomas (TFE-fusion RCCs) are caused by chromosomal
translocations that lead to overexpression of the TFEB and TFE3 genes (Kauffman et al., 2014).
The mechanisms leading to kidney tumor development remain uncharacterized and effective
therapies are yet to be identified. Hence, the need to model these diseases in an experimental
animal system (Kauffman et al., 2014). Here, we show that kidney-specific TFEB overexpression in
transgenic mice, resulted in renal clear cells, multi-layered basement membranes, severe cystic
pathology, and ultimately papillary carcinomas with hepatic metastases. These features closely
recapitulate those observed in both TFEB- and TFE3-mediated human kidney tumors. Analysis of
kidney samples revealed transcriptional induction and enhanced signaling of the WNT b-catenin
pathway. WNT signaling inhibitors normalized the proliferation rate of primary kidney cells and
significantly rescued the disease phenotype in vivo. These data shed new light on the mechanisms
underlying TFE-fusion RCCs and suggest a possible therapeutic strategy based on the inhibition of
the WNT pathway.
DOI: 10.7554/eLife.17047.001
Introduction
The MIT/TFE family of bHLH leucine zipper transcription factors includes the MITF, TFEB, TFE3 and
TFEC genes, which are master regulators of cell homeostasis, growth and differentiation
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(Levy et al., 2006; Sardiello et al., 2009; Settembre et al., 2011). All family members are able to
both homodimerize and heterodimerize with each other through their bHLH-LZ domain
(Hemesath et al., 1994). These transcription factors bind a DNA sequence called the M-box and a
non-canonical E-box sequence (TCATGTG, CATGTGA or TCATGTGA) (Hemesath et al., 1994;
Aksan and Goding, 1998). A large body of evidence indicate that they play an important role in
many cellular and developmental processes.
TFEB was found to regulate a large gene network, named Coordinated Lysosomal Expression
and Regulation (CLEAR). This network includes many genes involved in lysosomal biogenesis and
autophagy (Sardiello et al., 2009; Palmieri et al., 2011). Several studies have shown that TFEB
responds to a variety of stimuli and stress conditions, such as starvation, and acts as a master regula-
tor of the lysosomal-autophagic pathway and of cellular clearance (Ballabio, 2016; Roczniak-
Ferguson et al., 2012; Sardiello et al., 2009; Settembre et al., 2011, 2012; Settembre and
Medina, 2015; Martina et al., 2014b). Recent data indicate that the TFEB and TFE3 genes regulate
a similar set of genes and have partially redundant function (Martina et al., 2014a).
Renal cell carcinomas originate from the renal epithelium and include several subgroups defined
according to their histological phenotype. The most frequent RCCs are papillary (15–20%), Clear
Cells (65–70%) and cromophobe (5–10%) (Amin et al., 2002). In these categories, mutations in 12
different genes (VHL, MET, FH, FLCN, SDHB, SDHC, SDHD, TSC1, TSC2, PTEN, MITF and BAP1)
have been associated with an increased susceptibility of developing RCC (Linehan and Ricketts,
2013). TFE-RCCs are a group of renal cell carcinomas caused by chromosomal translocations involv-
ing TFEB and TFE3 genes (Kauffman et al., 2014) and representing around 2% of all RCCs
(Komai et al., 2009), and almost 12% of papillary type II RCCs (Linehan et al., 2015).
Recent TCGA analyses revealed that the gene fusions caused by chromosomal translocations
involving TFEB and TFE3 are the only recurrent translocations in the kidney (Linehan et al., 2015;
Malouf et al., 2014). In the case of TFEB, a recurrent chromosomal translocation t(6;11) (p21;q13)
involves the promoter of the non-coding Alpha gene and the transcription factor EB (TFEB)
(Argani et al., 2001, 2005). As a consequence, TFEB falls under the control of the strong Alpha
gene promoter, resulting in a high (up to 60-fold) overexpression of a structurally normal TFEB pro-
tein (Kuiper et al., 2003). More recently, additional TFEB translocation partners were described,
such as the KHDBRS2 (inv(6) (p21;q11)) (Malouf et al., 2014) and the CLTC (t(6;17) (p21;q23))
(Durinck et al., 2015) genes. Tipically, these tumors show nests of epithelioid cells with clear cyto-
plasm, known as clear cells (CCs), and clusters of small cells, usually around the multi-layered base-
ment membrane (mBM) made up of hyaline material (Argani et al., 2005). Some cases presented
with areas of a tubular or cystic structure covered by a single layer of flattened cuboidal to columnar
cells with clear cytoplasm, mimicking clear cell RCC with cystic changes (Rao et al., 2012). Currently,
TFEB translocation, overexpression and nuclear localization are considered as a diagnostic marker
for the disease. Initially, these tumors were mainly observed in pediatric patients, but now they are
considered relatively common in young adults (Komai et al., 2009). The mechanisms leading from
TFE3/TFEB gene overexpression to kidney tumor development remain largely uncharacterized, thus
the need for modeling these diseases in experimental animal systems for the identification of effec-
tive targeted therapies.
Here, we show the generation and characterization of two different transgenic mouse lines that
overexpress TFEB specifically in the kidney in a constitutive and inducible manner, respectively,
which recapitulate both the cystic changes and the cancer phenotype of the human pathology. An
extensive molecular and biochemical characterization of kidneys, as well as of primary kidney cells,
derived from these mice revealed a significant hyper-activation of the WNT pathway, suggesting
that this signalling pathway plays an important role in TFEB-driven kidney cancer. Finally, the use of
small molecules able to specifically inhibit the WNT pathway resulted in a significant rescue of both
the cystic and cancer phenotypes. These data may open the way to a new therapeutic strategy for
this type of tumors.
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Results
Generation of the transgenic mouse lines
To study the mechanisms underlying tumor development in TFEB-fusion RCC, we generated a trans-
genic mice that specifically overexpress TFEB in the kidney. We crossed a previously generated Tfeb
conditional overexpressing mouse line that carries Tfeb-3xFlagfs/fs under the control of a strong
chicken beta-actin (CAG) promoter (Settembre et al., 2011), herein referred to as Tfebfs/fs, with the
Cdh16Cre (Cadherin16Cre) mouse line, in which the Cre recombinase is specifically expressed in renal
tubular epithelial cells starting from embryonic stage E12.5 (Shao et al., 2002).
In addition, to assess the effects of Tfeb overexpression during kidney development, we gener-
ated a second transgenic line by crossing the Tfebfs/fs mice with a mouse line that carries a tamoxi-
fen-inducible CreErt2 element under the control of a Cdh16 promoter (Cdh16CreErt2promoter)
(Lantinga-van Leeuwen et al., 2006) (Figure 1—figure supplement 1A). Cdh16Cre::Tfebfs and
Cdh16CreErt2::Tfebfs double heterozygous mice were generated from these crossings (Figure 1—fig-
ure supplement 1B and C). We checked both the constitutive and inducible lines for renal Tfeb
overexpression and confirmed that Tfeb mRNA levels were highly increased, and further increasing
with time (Figure 1—figure supplement 1D). Consistently, immunoblot experiments revealed
increased levels of Tfeb-3xFLAG protein in kidneys from Cdh16Cre::Tfebfs and Cdh16CreErt2::
Tfebfs mice (Figure 1—figure supplement 1E).
Progressive cystic pathology in transgenic mouse lines
At sacrifice, kidneys from adult Cdh16Cre::Tfebfs and tamoxifen-treated Cdh16CreErt2::Tfebfs mice
completely filled the abdominal cavity (Figure 1A). An increase in kidney size from Cdh16Cre::
Tfebfs mice was observed starting at P12, with a sensible increase in size detected at P30
(Figure 1B). A striking increase in the Kidney to Body Weight (KW/BW) ratio was also observed at
this stage (Figure 1C). A severe enlargement of the kidneys and a significant increase in the Kidney
to Body Weight (KW/BW) ratio were also observed in Cdh16CreErt2::Tfebfs mice induced with tamoxi-
fen at several developmental stages (P12, P14, P30) (Figure 1—figure supplement 2A and B).
These abnormalities were less severe in mice induced at P30 (Figure 1—figure supplement 2B).
Survival time of Cdh16Cre::Tfebfs mice was approximately 3 months (Figure 1D). Interestingly, a late
induction of Tfeb overexpression in Cdh16CreErt2::Tfebfs mice resulted in a slower development of
the phenotype, with less severe kidney enlargement and overall increase in the survival rate
(Figure 1D). Renal function from Cdh16Cre::Tfebfs and Cdh16CreErt2::Tfebfs mice was severely
affected, as observed by the strong increase in blood urea and albuminuria (Figure 1—figure sup-
plement 2C). High-frequency ultrasound and histological analysis of kidneys from both Cdh16Cre::
Tfebfs and Cdh16CreErt2::Tfebfs mice revealed the presence of a severe cystic disease (Figure 1E, Fig-
ure 1—figure supplement 2D and E). In Cdh16Cre::Tfebfs mice, small cysts arose mainly from the
cortex and outer medulla at P12 and became significantly enlarged at P30. At P90, kidney architec-
ture was completely disrupted by cysts (Figure 1F). Cdh16CreErt2::Tfebfs mice induced at P12 with
tamoxifen and sacrificed at P90 showed a higher number of smaller cysts in both cortex and outer
medulla (Figure 1F). Cysts were also observed in Cdh16CreErt2::Tfebfs induced at P14 and, to a lesser
extent, at P30 (Figure 1—figure supplement 2E). Tubular epithelial cells lining the cysts showed
high levels of cadherin 16, indicating the presence of Cdh16Cre-mediated Tfeb overexpression in
these cells (Figure 1G). Histological analysis revealed that cysts from Cdh16Cre::Tfebfs mice were
positive for AQP2 and THP and negative for megalin, indicating that they originate from collecting
ducts and distal tubules and not from proximal tubules. Notably, the largest cysts were almost
completely negative to all tubular markers, suggesting that they became undifferentiated. Con-
versely, cysts from Cdh16CreErt2::Tfebfs mice were positive to megalin and THP, indicating that they
arose from proximal and distal tubules (Figure 1H, Figure 1—figure supplement 3). These differen-
ces in cyst origin have already been described in other polycystic kidney disease mouse models and
have been attributed to intrinsic differences of specific renal segments at different developmental
stages (Lantinga-van Leeuwen et al., 2007; Happe´ et al., 2009; Leonhard et al., 2016;
Piontek et al., 2007).
Cysts were lined by either a single layer-flattened cuboidal epithelium (sCy), or by a multilayer
epithelium (mCy), indicating a de-regulation of tubular cell proliferation (Figure 1I). We also noticed
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Figure 1. Tfeb overexpressing mice display cystic kidneys. Morphological analyses were performed on Cdh16Cre and Cdh16Cre::Tfebfs, and on tam-
treated Cdh16CreErt2 and Cdh16CreErt2::Tfebfs mice. (A) Representative images of the abdominal cavity at P90. (B) Kidney size at different stages (p=days
post-natal). (C) Relative ratio of kidney-to-body weight (KW/BW). Data from males (M) and females (F) are shown separately as means of Cdh16Cre::
Tfebfs to Cdh16Cre KW/BW ratio. Three-way Anova was applied (factors: gender, time, genotype). (D) Evaluation of the survival of Cdh16Cre::Tfebfs and
Figure 1 continued on next page
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the presence of very enlarged cells with a clear cytoplasm, which are commonly known as Clear Cells
(CCs) (Krishnan and Truong, 2002) (Figure 1I). Sirius Red staining showed the presence of fibrosis
and protein casts and revealed a significant accumulation of collagen inside the affected kidneys, as
well as the presence of regions surrounded by multi-layered basement membranes (mBM)
(Figure 1I). Importantly, the presence of Clear Cells, fibrosis and mBMs are characteristic features of
kidneys from human patients with TFEB-fusion RCC (Rao et al., 2012).
Identification of papillary renal cell carcinoma and of liver metastases
18F-FDG PET analysis showed a higher glucose consumption in the kidneys of transgenic animals
compared to controls, indicating a higher rate of glucose metabolism and suggesting a neoplastic
transformation (Figure 2A). Similarly with PET analysis, HE and Ki67 stainings of the kidneys of
Cdh16Cre::Tfebfs mice revealed progressive hyperproliferation, which evolved into Ki67-positive neo-
plastic papillae at 5 months (Figure 2B). Neoplastic nodules, micropapillae and Hobnail-like cells,
and mitotic spindles were detected at P12, 1 month, and 5 months, respectively (Figure 2C–F).
Focal microcalcifications (Figure 2G), together with Clear Cells, and nests of neoplastic cells
(Figure 2H) were also detected in Cdh16CreErt2::Tfebfs mice.
Kidneys from both Cdh16Cre::Tfebfsand Cdh16CreErt2::Tfebfs mice presented numerous neoplastic
lesions with both solid and cystic aspects, ranging from 0.102 to 2.93 mm and sometimes showing
local invasion of the surrounding stroma (Figure 2I). Most importantly, liver metastases ranging from
0.9 to 3.8 mm, were found in both Cdh16Cre::Tfebfsand Cdh16CreErt2::Tfebfsmice. In Cdh16Cre::
Tfebfs animals, they were detected starting from P90 with an incidence of 23% (5 cases out of 21
Cdh16Cre::Tfebfsmice older than 3 months). These metastases were positive for PAX8, that is a well-
established marker for primary and metastatic RCC (Ozcan et al., 2012; Shen et al., 2012) and
CDH16, which is a specific renal protein (Shen et al., 2012), while they were negative for the bile
ducts and cholangiocarcinoma marker CK7 (Cytokeratin 7), consistent with their renal origin
(Figure 2L).
TFEB overexpression results in the induction of the canonical WNT
pathway
To characterize the molecular mechanisms and identify the relevant pathways leading from TFEB
overexpression to tumor development, we performed transcriptome analysis on kidney samples
from Cdh16Cre::Tfebfs and Cdh16Cre mice at P0 (GSE62977-KSP_P0 dataset) and at P14 (GSE63376-
KSP_P14 dataset) (see Materials and methods) and found that Tfeb overexpression perturbed the
kidney transcriptome in a statistically significant manner (Figure 3—source data 1 and 2, see also
Materials and methods). Targeted analysis of the transcriptomic data revealed a significant induction
of genes belonging to both ErbB and WNT signaling pathways. This was confirmed by real-time PCR
Figure 1 continued
tam-treated Cdh16CreErt2::Tfebfs mice. Mantel-Cox test was applied (Cdh16CreErt2::Tfebfs tam P12/tam P14 p-value 0.02; Cdh16CreErt2::Tfebfs tam P12/P30
p-value<0.0001). (E) Haematoxylin and Eosin (HE) staining of kidneys. Enlarged panels show cyst growth over time. (F) Number (left graph) and area
(right graph) of kidney cysts in Cdh16Cre::Tfebfs, and Cdh16CreErt2::Tfebfs mice. Number of cysts is shown as an average (± SEM) with bars sub-divided
according to the dimension of the cysts. Cyst areas are presented as independent values (dots) with lines representing the means. Three-way (cyst
number) and two-way (cyst area) Anova was applied. Cor, cortex; oMed, outer medulla; iMed, inner medulla. (G) Cadherin16 (CDH16) staining of
kidneys from P30 mice. (H) Megalin, THP and AQP2 stainings in P90 Cdh16CreErt2::Tfebfs mice. (I) PAS and Sirius Red staining. PAS staining shows the
presence of single-layered or multi-layered cysts, and the presence of Clear Cells (CCs). SR staining shows areas of interstitial fibrosis, multi-layered
basement membrane and protein casts. Asterisks, protein casts; sCy, simple Cysts; mCy, multilayered Cy; IF, Interstitial Fibrosis; mBM, multi-layered
Basement Membrane. (*p<0.05, **p<0.01, ***p<0.001).
DOI: 10.7554/eLife.17047.002
The following figure supplements are available for figure 1:
Figure supplement 1. Generation of transgenic mouse lines with kidney-specific Tfeb overexpression.
DOI: 10.7554/eLife.17047.003
Figure supplement 2. Renal-specific Tfeb overexpression results in kidney enlargement and failure.
DOI: 10.7554/eLife.17047.004
Figure supplement 3. Characterization of cyst origin in Cdh16Cre::Tfebfs and Cdh16CreErt2::Tfebfs mice.
DOI: 10.7554/eLife.17047.005
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performed on Cdh16Cre::Tfebfs mice at several developmental stages. Moreover, real-time PCR
revealed an induction of Myc and Axin2 genes, which are, together with Ccnd1, well-established
WNT direct gene targets (Clevers, 2006) (Figure 3A and B, Tables 1 and 2). Kidneys from
Cdh16CreErt2::Tfebfs mice also had higher levels of all WNT-related genes that were identified in the
constitutive line, and of many of the ErbB-related genes (Figure 3—figure supplement 1A and B).
Based on these results, we checked the activation of both ErbB and WNT signaling pathways. No
evidence for an increase in the phosphorylation of AKT and ERK1/2 kinases (Arteaga and Engelman,
2014) was detected in P30 Cdh16Cre::Tfebfs kidneys or in primary kidney cells obtained from
Figure 2. Kidney-specific Tfeb overexpression is associated with cancer development in Cdh16Cre::Tfebfs and Cdh16CreErt2::Tfebfs mice. (A) 18F-FDG
PET/CT scan on P30 Cdh16Cre::Tfebfs mice. (B) HE and Ki67 staining performed on Cdh16Cre::Tfebfs mice at P1, P12, P30 and 5 months. Beginning at
P12 the increase in cyst size is associated with an increase in papillary proliferation that becomes completely neoplastic by 5 months. NP, Neoplastic
Papillae. (C–H) Representative images of neoplastic lesions at different stages: (C) neoplastic nodules (arrows) in P12 Cdh16Cre::Tfebfs mice; (D)
micropapillae (arrows) and (E) hobnail-like cells (arrows) in P30 Cdh16Cre::Tfebfs mice; (F) mitotic spindles (arrows) in 5-month-old Cdh16Cre::Tfebfs mice;
(G) microcalcifications (asterisk) in tam-treated Cdh16CreErt2::Tfebfs mice induced at P14 and sacrificed at 5 months; (H) neoplastic nests (NN) and clear
cells (CCs) in tam-treated Cdh16CreErt2::Tfebfs mice induced at P12 and sacrificed at P90. (I) HE staining of neoplastic lesions invading the surrounding
stroma (arrows) in Cdh16Cre::Tfebfs and in tam-treated Cdh16CreErt2::Tfebfs mice. (L) Liver metastases in 5 month-old Cdh16Cre::Tfebfs mice stained for
HE, Ki67, PAX8 and CK7.
DOI: 10.7554/eLife.17047.006
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Figure 3. Activation of ErbB and WNT signaling pathways in kidneys from Cdh16Cre::Tfebfs mice. Transcriptional and biochemical analyses were
performed on Cdh16Cre and Cdh16Cre::Tfebfs mice. (A,B) Tables show the relative increase of genes related to the ErbB (A) and WNT (B) pathways in
the microarray analyses performed on kidneys from P0 Cdh16Cre::Tfebfs mice. Graphs show real-time PCR validations performed on kidneys from
Cdh16Cre::Tfebfs mice at different stages (P0, P12, P30). Data are shown as the average (± SEM) of at least three Cdh16Cre::Tfebfs mice normalized
versus wild-type mice. (C,D) Immunoblot analyses performed on (C) P30 kidney tissues and (D) primary kidney cells isolated from Cdh16Cre::Tfebfs mice
to evaluate ErbB and WNT activation status. Each replicate is a distinct biological sample. ErbB signaling was assessed by looking at phosphoAKT
(Ser473) to total AKT ratio, and phosphoERK1 (T202/Y204)/ERK2(T185/Y187) to total ERK ratio; WNT signaling was assessed by quantifying b-catenin
and CCND1 (Cyclin D1) protein levels. Graphs represent the densitometry quantification of Western blot bands. Values are normalized to actin when
not specified and are shown as an average (± SEM) (*p<0.05, **p<0.01, ***p<0.001, two-sided, Student’s t test).
DOI: 10.7554/eLife.17047.007
Figure 3 continued on next page
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transgenic mice (Figure 3C and D), indicating that the ErbB pathway was not induced. Erk1/2 activa-
tion, as detected by pERK1/2, was observed only at late stages (Figure 3—figure supplement 2A).
The same result was observed in P14 and P30 tam-treated Cdh16CreErt2::Tfebfs mice (Figure 3—fig-
ure supplement 2B and C). Conversely, we detected increased levels of total b-catenin and CCND1
in P30 renal tissues and primary kidney cells (Figure 3C and D) and increased levels of active b-cate-
nin and of pLRP6 (Ser1490)/ LRP6 ratio in P30 and P90 renal tissues from Cdh16Cre::Tfebfsmice
(Figure 4A and B) and in P14 and P30 tam-treated Cdh16CreErt2::Tfebfs mice (Figure 4—figure sup-
plement 1). Moreover, b-catenin and active b-catenin staining of renal sections from Cdh16Cre::
Tfebfs mice was significantly enhanced (Figure 4C). These results indicate the presence of a strong
activation of the WNT signaling pathway in TFEB-overexpressing mice. Interestingly, the WNT path-
way is known to play a role in renal cyst development (Vainio and Uusitalo, 2000; Rodova et al.,
2002) and renal tumor formation, such as in VHL syndrome (Peruzzi and Bottaro, 2006) and Wilm’s
tumor (Koesters et al., 1999; Zhu et al., 2000; Kim et al., 2000). To investigate the role of TFEB in
WNT pathway activation, we performed luciferase assays using a TOP-FLASH Luciferase WNT-
reporter on immortalized kidney cell lines (HEK293 and HK2) co-transfected with TFEB and with
both b-catenin and TCF4 plasmids to stimulate WNT signaling. Luciferase activation was significantly
higher in cells transfected with TFEB compared to controls without TFEB. No changes were
observed when TFEB was transfected alone or only with b-catenin (Figure 5A and B). Together
these data suggest that TFEB is able to enhance WNT pathway activation.
Figure 3 continued
The following source data and figure supplements are available for figure 3:
Source data 1. Complete list of 294 genes (represented by 361 probesets) significantly induced (FDR0.05) in the KSP_P0 microarray dataset (GSE62977).
DOI: 10.7554/eLife.17047.008
Source data 2. Complete list of 628 genes (represented by 729 probesets) significantly induced (FDR0.05) in the KSP_P14 microarray dataset (GSE63376).
DOI: 10.7554/eLife.17047.009
Figure supplement 1. ErbB and WNT transcriptional profiles in Cdh16CreErt2::Tfebfs mice.
DOI: 10.7554/eLife.17047.010
Figure supplement 2. Biochemical analysis of ErbB signaling.
DOI: 10.7554/eLife.17047.011
Table 1. ErbB-related genes up-regulated in the microarray analyses. (A) List of six genes with a known role in ErbB signaling pathway
which are significantly up-regulated (FDR0.05) following TFEB overexpression in KSP_P0 microarray dataset (GSE62977). (B) One
gene with a known role in ErbB signaling pathway which are significantly up-regulated (FDR0.05) following TFEB overexpression in
KSP_P14 microarray dataset (GSE62977).
A
Probe set ID Gene symbol Gene title signed_ratio (KSP_P0/CTL)
1418350_at Hbegf heparin-binding EGF-like growth factor 2,194808473
1421943_at Tgfa transforming growth factor alpha 1,9286888
1421134_at Areg amphiregulin 1,631011877
1424638_at Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 1,628361867
1425855_a_at Crk v-crk sarcoma virus CT10 oncogene homolog (avian) 1,579433149
1450070_s_at Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1,507716537
B
Probe set ID Gene symbol Gene title signed_ratio (KSP_P14/CTL)
1421134_at Areg amphiregulin 1,221605795
DOI: 10.7554/eLife.17047.012
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Treatment with WNT inhibitors ameliorate the disease phenotype
Primary kidney cells derived from the renal cortex and medulla of Cdh16Cre::Tfebfs mice showed sig-
nificantly higher levels of proliferation compared to wild-type cells (Figure 5C). We tested whether
this hyperproliferative phenotype was sensitive to WNT inhibition. Strikingly, cell proliferation was
significantly dampened, in a dose-dependent way, by two small-molecules, PKF118-310 and
CGP049090 that specifically inhibit the WNT pathway by disrupting the interaction between b-cate-
nin and TCF4 (Avila et al., 2006) and are known to suppress cell proliferation in several types of can-
cers, both in vitro and in vivo (Wei et al., 2010; Wakita et al., 2001) (Figure 5D). Moreover, b-
catenin and CCND1 protein levels were highly reduced after PKF118-310 treatment (Figure 5E).
Based on the results obtained in primary kidney cells, we tested whether WNT inhibition could
ameliorate the disease phenotype in vivo. P21 Cdh16Cre::Tfebfs transgenic animals were treated with
daily IP injections of PKF118-310 for 30 days. At the end of the treatment, they showed an almost
complete rescue of both cystic and cancer phenotypes (Figure 6A). Indeed, treated animals showed
nearly normal KW/BW ratios (Figure 6B) and a significant reduction of many parameters of cystic
and neoplastic pathology, such as the number and size of cysts and neoplastic papillae, and levels of
Ki67 (Figure 6C and D, Figure 6—figure supplement 1, Figure 6—source data 1). We confirmed
that drug-treatment in Cdh16Cre::Tfebfs mice suppressed the WNT pathway both at the mRNA and
protein levels, as shown by the reduction of the mRNA levels of the WNT direct gene targets Cyclin
D1, Myc and Axin2 (Figure 6—figure supplement 2A), by the reduction of Cyclin D1 and MYC pro-
teins (Figure 6—figure supplement 2B) and by the decrease of Cyclin D1-positive nuclei in
Cdh16Cre::Tfebfs drug-treated mice (Figure 6—figure supplement 2C). Furthermore, WNT inhibition
resulted in normalization of expression levels of the gene encoding the transmembrane Glycoprotein
nmb (Gpnmb) (Figure 6E and F), a known marker of melanomas, gliomas and breast cancers, which
is also overexpressed in TFE-fusion ccRCCs (Malouf et al., 2014; Zhou et al., 2012). Interestingly,
Table 2. WNT-related genes up-regulated in the microarray analyses. (A) List of four genes with a
known role in WNT signaling pathway which are significantly up-regulated (FDR0.05) following TFEB
overexpression in KSP_P0 microarray dataset (GSE62977). (B) List of 10 genes with a known role in
WNT signaling pathway which are significantly up-regulated (FDR0.05) following TFEB
overexpression in KSP_P14 microarray dataset (GSE63376).
A
Gene symbol signed ratio (KSP_P0/CTL)
Rnf146 1,700903945
Fzd3 1,650328884
Kdm6a 1,565386988
Ccnd1 1,377411994
B
Gene symbol signed ratio (KSP_P14/CTL)
Rhou 1,639718601
Plcg2 1,601227563
Gata3 1,358534898
Fbxw2 1,262750602
Mark2 1,248332335
Axin1 1,21985179
Tab1 1,217280695
Psmb3 1,211737817
Ndrg2 1,193338279
Chd8 1,185904267
DOI: 10.7554/eLife.17047.013
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Figure 4. Molecular and histological analysis of WNT signaling. (A,B) Western blot analysis performed on (A) P30 and (B) P90 kidneys from Cdh16Cre::
Tfebfs mice to assess WNT signaling activation by looking at different proteins related to this pathway. Each replicate is a distinct biological sample.
p-LRP6 (Ser1490)/LRP6, active b-catenin, b-catenin and p-GSK3b (Ser9)/GSK3b protein levels were quantified by densitometry analysis of the Western
blot bands. Values are normalized to actin when not specified, and are shown as an average (± SEM) (*p<0.05, **p<0.01, ***p<0.001, two-sided
Figure 4 continued on next page
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this gene is a direct target of TFEB, based on promoter (Table 3) and ChiP-Seq analysis
(Sardiello et al., 2009) (Table 4).
Autophagy is not required for disease progression
Considering the known role of TFEB as a master regulator of the lysosomal-autophagy pathway
(Argani et al., 2001, 2005; Camparo et al., 2008; Davis et al., 2003), and the recent evidence indi-
cating that activation of autophagy driven by MiT/TFE genes plays an important role in pancreatic
cancer (Perera et al., 2015), we tested whether autophagy plays a role in TFE-tRCC development.
We analyzed the expression levels of a well-characterized panel of TFEB target genes known to be
involved in lysosomal biogenesis and autophagy in Cdh16Cre::Tfebfs mice. Surprisingly, no significant
changes in the expression levels of these genes were detected in Cdh16Cre::Tfebfs compared to wild
type mice, with a few exceptions (Figure 6—figure supplement 3A). Consistently, immunoblot anal-
ysis of the autophagy marker LC3 in kidneys from transgenic mice did not reveal any significant
changes compared to control littermates (Figure 6—figure supplement 3B). Furthermore, to test
the role of autophagy in the pathogenesis of TFE-tRCC we crossed Cdh16Cre::Tfebfs mice with
autophagy-deficient Atg7flox/flox mice. No changes in kidney size or in the cystic phenotype were
observed in TFEB overexpressing/autophagy-deficient double transgenic mice (Atg7flox/flox::
Cdh16Cre::Tfebfs), herein referred to Atg7flox/flox::Cdh16Cre::Tfebfs, compared to Cdh16Cre::
Tfebfs mice (Figure 6—figure supplement 3C–E). Interestingly, most of the double transgenic ani-
mals died at approximately 1 month of age, suggesting that the combination of TFEB overexpres-
sion with autophagy inhibition in the kidney is toxic. This may be due to the previously described
increase in sensitivity to oxidative stress of kidney-specific autophagy-deficient mice (Liu et al.,
2012). These results suggest that autophagy does not play a critical role in the development of TFE-
tRCC phenotype.
Discussion
Kidney cancers associated with translocations of TFE genes represent a major unmet medical need
(Argani et al., 2005; Komai et al., 2009; Malouf et al., 2014). Unfortunately, little is known about
the mechanisms underlying this type of tumors.
In most cases, TFEB-tRCCs are associated to a well-characterized chromosomal translocation
involving the TFEB gene and the non-coding Alpha gene, generating the alpha-TFEB fusion (t
(6;11) (p21.2;q13) (Davis et al., 2003; Kuiper et al., 2003). Until recent reports, TFEB breakpoints
were in all cases observed within a 289 bp cluster region (BCR) upstream exon 3, thus retaining the
entire TFEB coding sequence (Davis et al., 2003; Argani et al., 2005; Inamura et al., 2012). As a
consequence, the chromosomal translocation leads to a promoter substitution of the TFEB gene,
and to a strong up-regulation of TFEB transcript and protein up to 60-times (Kuiper et al., 2003).
Only recently, a new breakpoint was identified within exon 4, but the protein size appears to be the
same as the wild-type protein (Inamura et al., 2012). In rare cases of RCCs, TFEB translocation part-
ners were the KHDBRS2 (inv(6) (p21;q11)) (Malouf et al., 2014) and the CLTC (t(6;17) (p21;q23))
genes (Durinck et al., 2015). The situation of TFE3 chromosomal translocations appears to be more
complicated. TFE3 was found to be involved in translocations with five known gene partners (i.e.
PRCC, ASPSCR1, SFQP, NONO, CLTC) leading to the generation of fusion proteins. The identifica-
tion of multiple TFE3-gene partners and the characterization of two TFE3-fusion proteins (TFE3-
NONO, TFE3-SFQP) (Clark et al., 1997) strongly suggested that RCC is caused by TFE3, rather than
by its partners (Kauffman et al., 2014). Indeed, TFE3 fusion protein resulted to be much more sta-
ble and transcriptionally active than the wild-type protein (Weterman et al., 2000). Together, these
Figure 4 continued
Student’s t test). (C) Immunohistochemistry staining of CDH16, b-catenin and active b-catenin proteins performed on P30 kidney tissues from Cdh16Cre::
Tfebfs mice.
DOI: 10.7554/eLife.17047.014
The following figure supplement is available for figure 4:
Figure supplement 1. Molecular analysis of WNT signaling pathway in Cdh16CreErt2::Tfebfs animals.
DOI: 10.7554/eLife.17047.015
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Figure 5. Inhibition of WNT signaling rescues the hyper-proliferative phenotype of kidney cells from Cdh16/Tfeb mice. (A,B) Activity of the TCF/LEF
reporter TOP-FLASH. Luciferase activity after co-transfection of b-catenin and TCF plasmids in HEK293 (A) and HK2 (B) cells with and without Tfeb
overexpression. Values are shown as an average (± SEM) of each point in duplicate, normalized to the Renilla values and to the basal condition. Data
are representative of three independent experiments. (C) MTT tetrazolium reduction assay (MTT) was used to evaluate proliferation of primary kidney
Figure 5 continued on next page
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data suggest that the first step, and driving force, of the disease pathological cascade is the overex-
pression of active TFEB and TFE3 proteins, which is likely associated to an increase of their function
as transcription factors.
Currently, there are no model systems to study the mechanisms underlying TFE-tRCC kidney
tumors and to identify and test new therapeutic strategies. Until now, very limited data were avail-
able on the biological pathways involved in these tumors. Argani et al. (Argani et al., 2010)
reported activation of the mTOR pathway in TFE-tRCC patients compared to ccRCCs, as shown by
increased phosphorylation levels of the downstream mTOR target S6. Unfortunately, selective
mTORC1 inhibition performed on patients with TFE-tRCCs did not improve the disease phenotype
(Malouf et al., 2010). Up-regulation of the MET-tyrosine kinase receptor, which in turn activates
HGF-signaling, was detected in TFE-tRCC patients by in vitro assays (Tsuda et al., 2007), but subse-
quent analyses on TFE3-renal samples failed to identify activated MET protein (Kauffman et al.,
2014). The lack of mechanistic insights in TFE-tRCCs have hampered the identification of effective
therapeutic strategies (Kauffman et al., 2014). Some patients with metastatic TFE3-tRCC have been
treated with inhibitors of ErbB receptors and of the mTOR pathway. Unfortunately, most of these
patients relapsed after an initial period of remission (Parikh et al., 2009; Wu et al., 2008).
The lack of knowledge of the mechanisms underlying TFE-tRCCs prompted us to generate trans-
genic mouse models that overexpress TFEB in the kidney, thus mimicking the human disease situa-
tion. We generated two transgenic mouse models overexpressing TFEB in the epithelial cells of the
kidney in either a constitutive (Cdh16Cre::Tfebfs) or an inducible (Cdh16CreErt2::Tfebfs) manner. A
severe renal cystic pathology associated with a significant increase in renal size was observed in
these mice. In the constitutive model, cysts arose from the collecting ducts and distal tubules,
whereas in the inducible one they derived from proximal and distal tubules.
We observed that cysts were either single- or multi-layered. Epithelial cells lining the mono-lay-
ered cysts often lost their cuboidal shape, becoming flattened. Further analyses revealed the pres-
ence of protein casts inside the cysts and multi-layered basal membranes in the regions surrounding
the cysts, due to collagen deposition. Interestingly, the presence of fibrosis, mBMs and tubular or
cystic structures covered by a single layer of flattened, cuboidal, and columnar cells is also observed
in human patients affected by TFEB-tRCCs (Rao et al., 2012, 2013). Finally, in both types of trans-
genic lines, we observed the presence of highly enlarged cells with a clear cytoplasm, that closely
resemble the ’Clear Cells’ found in human patients with RCC (Rao et al., 2012).
Transgenic mice also displayed a higher glucose metabolism, as shown by PET-scan performed in
P30 animals suggesting the presence of renal cancer. At P12, Cdh16Cre::Tfebfs mice already pre-
sented cystic changes together with neoplastic nodules that were Ki67-positive. The progressive
hyper-proliferation of these nodules resulted in the development of micropapillae starting from P30,
which evolved into neoplastic papillae in 5-month-old mice. Finally, liver metastases positive for
PAX8 and CDH16 and neoplastic nests were observed in older animals. These data indicate that
these newly generated transgenic lines bear all major histological and phenotypic features of human
TFE-tRCC (Kauffman et al., 2014; Rao et al., 2012, 2013), thus representing excellent models to
study this disease.
To identify the effect of TFEB overexpression on the kidney transcriptome, we performed micro-
array analysis on kidney samples from P0 Cdh16Cre::Tfebfs mice. Unexpectedly, transgenic mice did
not show a significant induction of the autophagy machinery and crossing of these animals with an
Figure 5 continued
cells derived from Cdh16Cre::Tfebfs mice. Values are shown as an average (± SEM) of each point in triplicate and normalized versus wild-type mice. Data
are representative of three independent experiments. (D) MTT proliferation assays of primary kidney cells treated independently with two WNT
signaling inhibitors, PKF118-310 and CGP049090, added at different dosages for 24 hr. 0 mm represents the basal proliferation of cells. Values are
shown as means (± SEM) of three replicates per point normalized to the vehicle (DMSO), added at the same concentration, and versus the
Cdh16Cre cells without drug treatment. Results are representative of three independent experiments. Two-way Anova was applied (factors: cell
genotype, treatment). (E) Immunoblot analysis on primary kidney cells treated with Drug (PKF118-310) or Vehicle (DMSO) for 24 hr at 1.6 mM. Graphs
show the densitometry quantifications of Western blot bands. Values are normalized to actin and are shown as averages (± SEM) (Cor, cortex; Med,
medulla). (*p<0.05, **p<0.01, ***p<0.001).
DOI: 10.7554/eLife.17047.016
Calcagnı` et al. eLife 2016;5:e17047. DOI: 10.7554/eLife.17047 13 of 26
Research article Cancer Biology Human Biology and Medicine
Figure 6. Treatment with WNT inhibitor attenuates cystic and neoplastic phenotypes. Morphological, histological and biochemical analyses performed
on Cdh16Cre::Tfebfs mice treated with Vehicle (DMSO) or Drug (PKF118-310). (A,B) Kidney images (A) and sizes (KW/BW) (B) from Cdh16Cre::Tfebfs mice
injected intraperitoneally (IP) either with vehicle or drug at 0.85 mg/kg. KW/BW ratios are shown as means (± SEM) and values are normalized to the
Cdh16Cre animals treated with vehicle. Two-way ANOVA was applied (factors: treatment, genotype). (C) Ki67 staining of kidneys from Cdh16Cre::Tfebfs
Figure 6 continued on next page
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autophagy deficient Atg7flox/flox mouse line failed to revert the disease phenotype, thus suggesting
that autophagy does not play an essential role in the pathogenesis of this disease.
Transcriptome analysis revealed a significant induction of genes involved in the WNT pathway,
such as WNT direct target genes Ccnd1, Myc and Axin2 and WNT-related genes Fzd3, Rnf146 and
Kdm6a. This transcriptional induction was consistent with increased protein levels of total b-catenin,
active b-catenin, CCND1 and pLRP6 (Ser1490)/ LRP6 ratio. Furthermore, an induction of the phos-
pho-GSK3b (Ser9)/ GSK3b ratio, an inactive form of the GSK3b kinase, was detected at later stages.
Hyper-activation of the WNT pathway was also observed in cortical and medullary primary kidney
cells derived from Cdh16Cre::Tfebfs mice. Most importantly, luciferase assays performed on HEK-293
and HK-2 cells revealed that TFEB overexpression resulted in a significant enhancement of WNT
pathway activation.
WNT signalling is of central importance for the development of many organs and has been impli-
cated in tumor pathogenesis at different sites such as skin (Robbins et al., 1996), brain
(Zurawel et al., 1998), liver (de La Coste et al., 1998) and prostate (Voeller et al., 1998). Its activa-
tion requires the formation of the WNT signalosome, resulting from the binding of WNT ligands to
Frizzled (Fzd) receptors. This mediates the interaction of Fzd with LRP5/6 proteins. Fzd-LRP5/6 het-
ero-oligomerization is required to sequester the b-catenin degradation complex, containing several
kinases such as GSK3 and CK1. GSK3 is then able to phosphorylate LRP but not b-catenin. Active b-
catenin translocates into the nucleus and activates its target genes, such as MYC, AXIN2 and
Figure 6 continued
mice after treatment with vehicle or drug. Insets are enlargements of a single cyst. (D) Quantification of several parameters related to cysts and papillae
performed on kidney sections from vehicle- and PKF118-310-treated Cdh16Cre::Tfebfs mice. (E) Gpnmb mRNA fold activation in kidneys from Cdh16Cre::
Tfebfs and tam-treated Cdh16CreErt2::Tfebfs mice at different stages. Values are shown as means (± SEM) of at least three mice and each group is
normalized to the proper control (respectively Cdh16Cre and tam-treated Cdh16CreErt2). (F) Gpnmb fold activation in kidneys from Cdh16Cre::Tfebfs mice
treated with vehicle or PKF118-310. Values are shown as means (± SEM) of at least three animals per group and are all normalized versus the Cdh16Cre
mice treated with vehicle. (*p<0.05, **p<0.01, ***p<0.001, two-sided Student’s t test).
DOI: 10.7554/eLife.17047.017
The following source data and figure supplements are available for figure 6:
Source data 1. Numerical data of each parameter showed in Figure 6D and divided per genotype and treatment.
DOI: 10.7554/eLife.17047.018
Figure supplement 1. In vivo treatment of Cdh16Cre::Tfebfs mice with the WNT inhibitor PKF118-310 partially rescues cystic and neoplastic phenotypes.
DOI: 10.7554/eLife.17047.019
Figure supplement 2. In vivo treatment of Cdh16Cre::Tfebfs mice with the PKF118-310 drug inhibits WNT pathway overactivation.
DOI: 10.7554/eLife.17047.020
Figure supplement 3. Inhibition of autophagy in Tfeb overexpressing mice (Atg7flox/flox::Cdh16Cre::Tfebfs) does not affect the cystic phenotype.
DOI: 10.7554/eLife.17047.021
Table 3. GPNMB expression profiles and CLEAR sites. (A) Differentially expression of Gpnmb transcript in KSP_P0 (GSE62977), in
KSP_P14 microarray dataset (GSE63376) and in RCC dataset. (B) Sequence analysis of the CLEAR sites (i.e. the consensus TFEB
binding sites) in the human and murine promoter region of Gpnmb.
A
Probe set
ID
Gene
symbol
Gene title Representative
public ID
Ensembl ratio (KSP_P0/
CTL)
ratio (KSP_P14/
CTL)
ratio (RCC/
CTL)
1448303_at Gpnmb glycoprotein
(transmembrane) nmb
NM_053110 ENSMUSG00000029816 10,61358979 4,926015853 141,4101213
B
Gene Score Sequence Chrom ABS start ABS end TSS_position
Gpnmb 0,8731563 GGGGCAAGTGACTC chr6 49036518 49036531 1
Gpnmb 0,803943 ACATCACATGATCT chr6 49036587 49036600 70
GPNMB 0,8484716 CCATCACATGATCC chr7 23286328 23286341 13
DOI: 10.7554/eLife.17047.022
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CCND1 (Clevers, 2006), by interacting with the TCF4/LEF1 transcription factors (Voronkov and
Krauss, 2013).
Interestingly, hyper-activation of the WNT pathway was recently detected in a melanoma cell line
in which MITF, another member of the MiT/TFE family, was overexpressed, leading to an expansion
of the endo-lysosomal compartment that in turn was able to concentrate and relocate the WNT sig-
nalosome/destruction complex and consequently to enhance WNT signaling (Ploper et al., 2015). In
addition, several studies have linked alterations in the regulation of the b-catenin pathway to abnor-
malities of kidney development and function (Vainio and Uusitalo, 2000). Indeed, b-catenin is nec-
essary for proper regulation of the PKD1 promoter (Rodova et al., 2002), that is mutated in 85% of
patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Furthermore, the WNT path-
way is also known to play a role in renal tumor formation, such as in VHL syndrome (Peruzzi and Bot-
taro, 2006) and Wilm’s tumor (Koesters et al., 1999; Zhu et al., 2000; Kim et al., 2000). Mice
lacking the Apc gene specifically in the kidney are prone to the development of cystic renal cell car-
cinomas (Sansom et al., 2005). Finally, cytoplasmic accumulation of b-catenin was observed in
patients with TFE3-tRCC, suggesting the presence of a possible link between TFE-factors and WNT-
signaling components (Bruder et al., 2007). Together these studies reveal a strong link between
hyper-activation of WNT signaling and tumorigenesis in the kidney and reinforce our finding of WNT
hyper-activation in TFEB transgenic mice as a critical step of the disease pathogenesis.
Based on this evidence, we postulated that treatment with WNT inhibitors had beneficial effects
on TFE-tRCCs. To test this hypothesis, we treated primary kidney cells from Cdh16Cre::Tfebfs mice
with two small molecules, PKF118-310 and CGP049090, able to inhibit the WNT pathway by disrupt-
ing the interaction between b-catenin and TCF-4 (Avila et al., 2006). Drug treatments significantly
reduced the hyper-proliferation rate observed in cells from transgenic mice, bringing it to normal
levels. Therefore, we sought to reproduce these data in vivo by treating Cdh16Cre::Tfebfs mice with
WNT inhibitors. Administration of the PKF118-310 molecule or vehicle for 30 days resulted in a sub-
stantial reduction of several important parameters, such as kidney size, cyst number and size, Ki67
index and the number of neoplastic papillae. Moreover, drug-treated Cdh16Cre::Tfebfs animals
Table 4. List of 11 genes shared between the KSP_P0 dataset and from an HeLa TFEB-overexpressing ChIP-Seq dataset.
Gene
symbol
signed_ratio
(KSP_P0/CTL) chromosome start stop
peak
tags
distance from
5’ end of gene RefSeq ID symbol ID
ABS
distance
Elf3 1,881188134 chr1 2E
+08
201978977 8 -712 NM_001114309 ELF3 ETS-related transcription
factor Elf-3
712
Gna13 1,504591673 chr17 6E
+07
63053379 8 -58 NM_006572 GNA13 guanine nucleotide-
binding protein subunit
58
Ankrd12 1,599217835 chr18 9E
+06
9137025 15 0 NM_015208 ANKRD12 ankyrin repeat domain 12
isoform 1
0
Atp6v1c1 1,658752808 chr8 1E
+08
104033525 15 0 NM_001695 ATP6V1C1 V-type proton ATPase
subunit C 1
0
Bhlhe40 2,03490115 chr3 5E
+06
5021164 10 0 NM_003670 BHLHE40 class E basic helix-loop-
helix protein 40
0
Gpnmb 10,61358979 chr7 2E
+07
23286524 9 0 NM_002510 GPNMB transmembrane
glycoprotein NMB
isoform b
0
Kdm6a 1,58385317 chrX 4E
+07
44732628 33 0 NM_021140 KDM6A lysine-specific
demethylase 6A
0
Lats2 1,761917857 chr13 2E
+07
21636098 22 0 NM_014572 LATS2 serine/threonine-protein
kinase LATS2
0
Ppargc1a 2,713649997 chr4 2E
+07
23891989 11 0 NM_013261 PPARGC1A peroxisome proliferator-
activated receptor gamma
0
Rnf146 1,700903945 chr6 1E
+08
127588198 14 0 NM_030963 RNF146 ring finger protein 146 0
Usp2 2,284889961 chr11 1E
+08
119252760 8 0 NM_004205 USP2 ubiquitin specific
peptidase 2 isoform a
0
DOI: 10.7554/eLife.17047.023
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showed a significant decrease in the mRNA levels of Gpnmb, a known marker of melanomas, glio-
mas and breast cancer, which was reported to be overexpressed in TFE-fusion ccRCCs
(Malouf et al., 2014; Zhou et al., 2014). Interestingly, we also found that Gpnmb is a direct tran-
scriptional target of TFEB (Sardiello et al., 2009).
This study provides direct evidence that overexpression of TFEB in the kidney is able to generate
a severe cystic pathology associated with the development of kidney cancer and liver metastases,
thus mimicking the cancer phenotype associated with human TFE-fusion ccRCCs chromosomal trans-
locations. Thus, the transgenic mouse lines that we generated represent the first genetic animal
models of renal cell carcinoma. The study of these mice revealed that WNT activation plays a crucial
role in TFE-tRCCs and that WNT inhibitors can be used to rescue the phenotype of our transgenic
mouse models, suggesting that targeting WNT signaling could be a promising therapeutic approach
for the treatment of TFE-tRCC patients.
Materials and methods
Mouse models
Tfebfs/fs transgenic mice (generated by Dr. Settembre [Settembre et al., 2011]) were crossed with a
kidney-specific Cdh16Cre (Cdh16, Cadherin 16) (Jackson laboratories RRID:IMSR_JAX:012237) and
Cdh16CreErt2 (generated by Dr. Peters [Lantinga-van Leeuwen et al., 2006]) mice. The Atg7 condi-
tional KO mice (Komatsu et al., 2005) (Atgflox/flox mice) was a generous gift from T.Eissa. Mice were
crossed with Cdh16Creand Tfebfs/fs mice to obtain kidney-specific Atg7 deletion and TFEB overex-
pression (Atgflox/flox: :Cdh16Cre::Tfebfs). All mice used were maintained in a C57BL/6 background
genotype. Cdh16Creand Cdh16Cre::Tfebfs mice were injected intra-peritoneally (IP) with tamoxifen at
a dosage of 100 mg/g of mouse weight for three consecutive days to obtain an efficient recombina-
tion. For the Kidney to Body weight ratio experiments, we analyzed at least three animals per geno-
type/sex/condition, but often the number was higher than 5. Experiments were conducted in
accordance with the guidelines of the Animal Care and Use Committee of Cardarelli Hospital in
Naples and authorized by the Italian Ministry of Health.
Cell culture, transfections and plasmids
Primary kidney cells were obtained following the protocol described in Leemans
et al. (Leemans et al., 2005). Briefly, kidneys were collected and uncapsulated. Tissue from the outer
cortex and inner medulla was cut into approximately 1 mm3 pieces, and subsequently digested by
1 mg/ml collagenase type 1A (Sigma- Aldrich, Saint Louis, MO) at 37˚C for 1 hr. After washing cells
with PBS, primary TECs were grown to confluence in DMEM-F12 culture medium supplemented with
10% FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Gibco; Invitrogen
Corp.), 1% ITSe and 1% S1 hormone mixture (Sigma-Aldrich) and were cultured in 5% CO2 at 37
degrees. TECs were identified by characteristic cobblestone-shaped morphology. Tfeb overexpres-
sion was confirmed by FLAG immunoblot (Figure 2). HEK293 (CRL-1573, RRID:CVCL_0045) and HK2
(CRL-2190, RRID:CVCL_0302) cells were purchased from ATCC. The identity of these cells have
been confirmed by STR profiling (http://web.expasy.org/cellosaurus/CVCL_00459) (http://web.
expasy.org/cellosaurus/CVCL_0302). No mycoplasma contamination was detected in these cells.
HEK293 cells were cultured in DMEM (Euroclone) supplemented with 10% FBS, 100IU/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine (Gibco; Invitrogen Corp.). HK2 cells were grown in
DMEM-F12 (Invitrogen) supplemented with 5% FBS, 100 IU/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine (Gibco; Invitrogen Corp.) and 1% ITSe. Cells were grown at 5% CO2 at 37
degrees. Human full-length TFEB-FLAG was previously described (Settembre et al., 2011). The Top-
Flash and FopFlash plasmids (Upstate), the pCS2+MT-Myc-tagged b-CATENIN (full-length b-CATE-
NIN), and the Evr2-Tcf1E plasmid (Tcf1E) were kindly provided by Dr. M. Plateroti.
Cells were transfected with Lipofectamine LTX and Plus reagent (Invitrogen) following the manu-
facturer’s protocol. Luciferase activity was measured 48 hr post-transfection using the Dual-Lucifer-
ase Reporter Assay System (Promega). To normalize transfection efficiency in reporter assays, the
HEK293 and HK2 cells were co-transfected with a plasmid carrying the internal control reporter
Renilla reniformis luciferase driven by a TK promoter (pRL-TK; Promega). Data are representative of
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three independent experiments and statistical significance was determined using Student’s t-test.
p<0.05 was considered as significant.
In vitro drug treatments and MTT proliferation assay
Cultured primary kidney cells derived from the cortex and medulla of Cdh16Cre and Cdh16Cre::Tfebfs
mice were seeded in 96-well plates at the density of 5  103 cells/well, maintained overnight at
37˚C, and incubated in the presence of the test compounds at the different concentrations. PKF118-
310 and CGP049090 were added at different dosages (0 mm, 0.2 mm, 0.4 mm, 0.8 mm, 1.6 mm,
3.2 mm) for 24 hr. 0 mm represents the basal proliferation of cells after 48 hr of plating. MTT assay
was used to assess cell proliferation. Briefly, 5 mg of MTT powder was solubilized in 1 mL of PBS
and filtered. Ten microliter of this solution was added to 100 ml of cell culture medium without phe-
nol red. At the end of the incubation time, cells were washed twice with PBS and incubated with
MTT-media solution to form formazan crystals. After 4 hr, media was removed and 100 ml/well of a
solubilisation solution was added to the cells (2.1 mL HCl 10 N, 500 mL isopropanol) for 4 hr at 37˚C
to obtain a complete solubilization of the crystals. As a readout, absorbance of the 96-well plate was
measured recording the Optical Density (OD) at 570 nm with a microplate spectrophotometer sys-
tem. Results are representative of three independent experiments performed on three different
Cdh16Cre and Cdh16Cre::Tfebfs mice. T-test is referred to cells without drug (0 mm) taken from
Cdh16Cre::Tfebfs mice versus cells without drug (0 mm) taken from Cdh16Cre mice. Data are represen-
tative of three independent experiments, and statistical significance was determined using Student’s
t-test. p<0.05 was considered as significant.
In vivo drug treatments
P21 Cdh16Creand Cdh16Cre::Tfebfs mice were injected IP daily, from Monday to Friday, with the
PKF118-310 drug at the dose of 0.85 mg/kg or with an equal amount of vehicle (DMSO). After 30
days from the beginning of the treatment, animals were sacrificed and kidneys were collected and
weighted and processed for further analyses. Six animals for each group and genotype were
collected.
Biochemical analysis
Plasma urea was measured using standardized clinical diagnostic protocols of the Academical Medi-
cal Center Amsterdam. Albumin (Bethyl Laboratories, Montgomery, TX) was measured in urines col-
lected for 24 hr in metabolic cages and was analyzed by following the manufacturer’s instructions.
High-frequency ultrasound and PET/CT scan analyses
All the imaging procedures were performed with mice under general anesthesia. Anesthesia was
produced in an induction chamber, saturated with 5% isoflurane (Iso-Vet 1000 mg/g Inhalation
Vapor, Piramal Healthcare UK Ltd., Northumberland, UK) in oxygen (2 L/min) and subsequently
maintained during all procedures with a conenose delivering isoflurane at 1.5% in oxygen at 2 L/min.
For High-frequency ultrasound, each mouse was placed in dorsal recumbency on a dedicated,
heated, small animal table (VEVO Imaging Station 2, FUJIFILM VisualSonics, Inc., Toronto, Ontario,
Canada) and hairs were removed with a small clipper and then with the application of a depilatory
cream, and a pre-warmed ultrasound-coupling gel was applied to the skin to improve ultrasound
transmission and reduce contact artefacts. A 40 MHz transducer (MS 550 D, FUJIFILM VisualSonics,
Inc., Toronto, Ontario, Canada) was mounted on the dedicated stand of the imaging station, and
B-mode and Color-Doppler mode images were obtained on the ultrasound equipment (VEVO 2100,
FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada).
Positron emission tomography (PET) coupled with computed tomography (CT) was performed
with a dedicated small animals PET/CT scanner (eXplore Vista, GE Healthcare), with a trans-axial field
of view of 6.7 cm and an axial field of view of 4.8 cm. Animals, fasted overnight, were injected under
general anesthesia in the lateral caudal vein with 300 mCi of [18F]-fluorodeoxyglucose (FDG). Mice
were left to recover from anesthesia under a heating lamp and PET/CT acquisitions were started
after 90 min of biodistribution. Static emission scans of 30 min with energy window of 250–700 keV
were acquired. The PET datasets were reconstructed by 2D FORE/3D OSEM algorithm and cor-
rected for random coincidences, scatter, physical decay to the time of injection (voxel size: 0.3875 
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0.3875  0.775 mm3). The mean specific uptake value (SUV) was obtained for each region of interest
using the visualization and analysis software of the scanner (version 4.11 Build 701, MMWKS Image
Software: Laboratorio de Imagen, HGUGM, Madrid, Spain).
Survival analysis
Survival curves were calculated for a period of 8 months on a total of 15 Cdh16Cre::Tfebfs mice, 10
Cdh16CreErt2::Tfebfs mice (tam P12), 12 Cdh16CreErt2 mice (tam P14) and 12 Cdh16CreErt2::Tfebfs mice
(tam P30) grown in the same animal facility, all in same background (C57BL/6). Values were plotted
by the product-limit method of Kaplan and Meier; statistical analyses were carried out applying the
Log Rank (Mantel-Cox) test.
Quantitative real-time PCR
Total RNA was isolated from frozen samples lysed in Trizol (Life Technologies) using a TissueLyser
(Qiagen) and following the recommended manufacturer’s protocol. Reverse transcription was per-
formed using QuantiTect Rev Transcription Kit (Qiagen). Finally, real-time PCR was performed using
SYBR Green (Roche Diagnostics) and performing the reaction in the LightCycler System 2.0 (Roche
Applied Science). The parameters of real-time PCR amplification were defined according to Roche
recommendations. To quantify gene expression, Gapdh mRNA expression was used as an internal
reference. All the values are shown as fold activation respect to w-type levels. Data are representa-
tive of three independent experiments and statistical significance was determined using Student’s t-
test. p<0.05 was considered as significant.
The following primers were used in this study: Gapdh; forward (fw) tgcaccaccaactgcttagc, reverse
(rev) tcttctgggtggcagtgatg; Tfeb; fw gcagaagaaagacaatcacaa, rev gccttggggatcagcatt; Ccnd1; fw
ccttgactgccgagaagttgtg, rev gttccacttgagcttgttcacca; Axin2; fw gatgcatcgcagtgtgaagg, rev ggttcca-
caggcgtcatctc; Myc; fw ccagcagcgactctgaagaa, rev acctcttggcaggggtttg; Fzd3; fw gcatctgggaga-
caacatgg, rev caggtctggacgactcatctg; Rnf146; fw agcggaggagaaaagactgc, rev
acatagccctttctcggtccg; Kdm6a; fw tgacagcggaggagagggag, rev ccttcatcctggcgccatct; Cdkn1a; fw
gtctgagcggcctgaagatt, rev caatctgcgcttggagtgat; HbEgf; fw tccacaaaccagctgctacc, rev
ccttgtggcttggaggagaa; Pak1; fw ttcctgaaccgctgtcttga, rev tcaggctagagaggggcttg; Areg; fw tattgg-
catcggcatcgtta, rev tgcacagtcccgttttcttg; Crk; fw cgcgtctcccactacatcat, rev tctcctattcggagcctgga;
Tgfa; fw agtgcccagattcccacact, rev cgtacccagagtggcagaca; Gpnmb, fw tggctacttcagagccacca, rev
ggcatggggacatctgctat.
Microarray hybridization
Total RNA (3 mg) was reverse transcribed to single-stranded cDNA with a special oligo (dT) 24
primer containing a T7 RNA promoter site, added 3’ to the poly-T tract, prior to second strand syn-
thesis (One Cycle cDNA Synthesis Kit by Affymetrix, Fremont, CA). Biotinylated cRNAs were then
generated, using the GeneChip IVT Labeling Kit (Affymetrix). Twenty microgram of biotinylated
cRNA was fragmented and 10 mg hybridized to the Affymetrix GeneChip Mouse 430A_2 microarrays
for 16 hr at 45˚C using an Affymetrix GeneChip Fluidics Station 450 according to the manufacturer’s
standard protocols.
For the analysis at P0, the total RNA was extracted from the kidney of three Cdh16Cre::Tfebfs
mice and of two control Cdh16Cre mice. For the analysis at P14, total RNA was extracted from the
kidney of three Cdh16Cre::Tfebfs P14 mice and three control Cdh16Cre P14 mice.
Microarray data processing
The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus
(GEO) (Edgar et al., 2002) and are accessible through GEO Series accession number GSE62977
(KSP_P0 dataset) and GSE63376 (KSP_P14 dataset) (KSP, Kidney specific). Low-level analysis to con-
vert probe level data to gene level expression was performed using Robust Multiarray Average
(RMA) implemented using the RMA function of the Bioconductor project (Gentleman et al., 2004).
Statistical analysis of differential gene expression
For each gene, a Bayesian t-test (Cyber-t) (Baldi and Long, 2001) was used on RNA normalized data
to determine if there was a significant difference in expression between Cdh16Cre::Tfebfs mice versus
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Cdh16Cre mice both at P0 (GSE62977-KSP_P0 dataset) and at P14 (GSE63376- KSP_P14 dataset).
p-Value adjustment for multiple comparisons was done with the False Discovery Rate (FDR) of Benja-
mini-Hochberg (Klipper-Aurbach et al., 1995). The threshold for statistical significance chosen was
FDR0.05. In the KSP_P0 dataset, we selected 361 probe-sets corresponding to 294 significantly
induced genes (GSE62977). In the KSP_P14 dataset, we selected 729 probe-set corresponding to
628 genes (GSE63376).
(Immuno-) histological analysis
Formalin-fixed, paraffin-embedded kidney sections (4 mm) were analyzed using standard hematoxylin
and eosin (HE) staining, periodic acid Schiff (PAS) staining, or Sirius Red (SR) staining. For immuno-
histochemistry procedures, sections were subjected to heat-mediated antigen retrieval procedure
(10 mM citrate buffer pH 6.0) followed by 1 hr preincubation with normal goat serum (1:200; Dako-
Cytomation, Glostrup, Denmark). After blocking of endogenous peroxidase activity for 15 min
in 0.1% H2O2 in water, sections were incubated with primary antibodies diluted in 1% BSA in PBS.
Following incubation with secondary antibody, immune reactions were revealed using NovaRed or
diaminobenzidine chromogen and counterstained with hematoxylin, dehydrated, and mounted.
Primary antibodies: rabbit polyclonal anti-megalin (1:750, Pathology LUMC, Leiden, the Nether-
lands), goat polyclonal anti-uromodulin (1:4000, Organon Teknika-Cappel,Turnhout, Belgium), rabbit
polyclonal anti-aquaporin-2 (1:4000 Calbiochem, Amsterdam, The Netherlands), rabbit polyclonal
anti-b-catenin (1:500, Santa Cruz sc-7199, RRID:AB_634603), rabbit monoclonal anti-active b-catenin
(1:800, Cell Signaling #8814, RRID:AB_11127203), rabbit polyclonal anti-cadherin16 (1:300, Novus
NBP159248, RRID:AB_11046440), rabbit polyclonal anti-ATG7 (1:300, Santa Cruz sc-33211, RRID:
AB_2062165), rabbit monoclonal anti-Ki67 (ABCAM ab16667, clone SP6, RRID:AB_302459, 1:200), a
rabbit polyclonal anti-PAX8 antibody (Proteintech, 10336-1-AP, RRID:AB_2236705, 1:1000) and a
mouse monoclonal anti-Cytokeratin 7 (Abcam, ab9021, RRID:AB_306947, 1:500). Secondary anti-
bodies: anti-rabbit envision HRP (DakoCytomation, Glostrup, Denmark), rabbit-anti-goat HRP
(1:100), power rabbit poly-HRP (Biocare Medical, M4U534L). For staining with Sirius Red, de-paraffi-
nized sections were incubated in 0.2% phosphomolybdic acid hydrate for 5 min and 0.1% Sirius red
for 90 min. Subsequently, sections were incubated for 1 min in saturated picric acid and then placed
in 70% ethanol, dehydrated and mounted.
Quantitative histology
Histomorphometric analysis were conducted on PAS and Ki67-stained sections. For the cyst charac-
terization, cyst number and area was calculated on PAS sections from three animals per genotype
and group. Cysts were hand-annotated and measured in the outer and inner cortex, and the outer
and inner medulla. Finally, they were sub-divided according to their size.
For the analyses performed on the drug- and vehicle-treated animals, the analysis was conducted
on Ki67-stained sections. The number and size of the cysts were defined within the areas identified
by the pathologist using ImageScope (Leica-Biosystems Nussloch GmbH).
Using the same method, the number of papillae was counted and the proportion of Ki-67 positive
nuclei on the total number of nuclei within the papillae was calculated. For these analyses, a total of
six Cdh16Cre::Tfebfs vehicle (DMSO)-treated and six Cdh16Cre::Tfebfs drug (PKF118-310)-treated ani-
mals were evaluated.
Antibodies and western blotting
Tissues were microdissected and disrupted using a TissueLyser (Qiagen). Cells or tissues were lysed
by solubilisation in lysis buffer (50 mM Tris at pH 7.9, 1% Triton X-100, 0,1% Tween 20, 150 mM
NaCl, 5 mMMgCl2, 10% glycerol) containing phosphatase (Roche) and protease (Sigma) inhibitors.
Protein concentration was measured by the Bradford method. Samples were mixed with Laemmli
lysis buffer, boiled and resolved by SDS-PAGE. Thereafter, proteins were blotted onto polyvinyli-
dene fluoride (PVDF) membranes and blocked for 1 hr with non-fat 5% milk or 5% BSA diluted in 1X
TBS, 0,1% Tween 20, according to the primary antibody protocol. Membranes were incubated with
primary antibodies overnight. Visualization was made by incubation with corresponding HRP-labeled
secondary antibodies (Calbiochem) followed by enhanced chemiluminescence (ECL) (Perkin Elmer,
Waltham, MA). Membranes were developed using a Chemidoc UVP imaging system (Ultra-Violet
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Products Ltd) and densitometric quantification was performed in unsaturated images using ImageJ
(NIH).
For Western blots, the following antibodies were used: anti-FLAG M2-HRP (Sigma, cat. A8592,
RRID:AB_439702, 1:1000), anti-actin (Sigma, cat. A2066, RRID:AB_476693, 1:5000), anti-btubulin
(Sigma, cat. T8328, RRID:AB_1844090 1:1000), anti-Human/Mouse/Rat Pan-Akt (R&D, cat.
MAB2055, RRID:AB_2224581, 1:500), Phospho-Akt (Ser473) (D9E) Cell Signaling, cat. #4060, RRID:
AB_2315049, 1:1000), anti-human, mouse, and rat ERK1/ERK2 (R&D, cat.216703, RRID:AB_2140121,
1:2000), anti-Human/Mouse/Rat Phospho- ERK1(T202/Y204)/ERK2 (T185/Y187) (R&D, cat. AF1018,
RRID:AB_354539 1:1000), anti-b-catenin (BD, cat. 610154, RRID:AB_397555 1:500), anti-active b-cat-
enin (Cell Signaling, cat. #8814, RRID:AB_11127203 1:1000), anti-Cyclin D1 (Cell Signaling, cat.
#2978, RRID:AB_10692801 1:1000), anti-LRP6 (Cell Signaling, cat. #3395, RRID:AB_1950408 1:1000),
anti-phospho-LRP6 (Ser1490) (Cell Signaling, cat. #2568, RRID:AB_2139327 1:1000), anti-GSK3b
(Cell Signaling, cat. #9315, RRID:AB_490890 1:1000), anti-phospho-GSK3b (Ser9) (Cell Signaling, cat.
#9323, RRID:AB_2115201 1:1000), anti MYC (Cell Signaling, cat. #5605, RRID:AB_1903938 1:1000).
Statistical analysis
GraphPad Prism (GraphPad Software, San Diego, CA) was used for all statistical analysis. Statistical
analyses of data were performed using Student’s t-test. One-way ANOVA and Tukey’s post-hoc tests
were performed when comparing more than two groups relative to a single factor (time or treat-
ment/genotype). Two-way and three-way ANOVA and Tukey’s post-hoc tests were performed when
comparing more than two groups relative to two or more factors. Mantel-Cox test was used for the
survival analysis. p<0.05 was considered significant.
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